Company intelligence / Profile preview

Protherapeutics

Manchester, New Hampshire, United States

Ownership: Private
Employees: ~10
Development stage: Other

Overview

PRO Therapeutics received a $1.8 million Direct-to-Phase-2 Small Business Innovation Research (SBIR) grant from the National Institute of Health to conduct pre-clinical studies on their tissue-engineered graft for rotator cuff repair. The technology, developed from University of Michigan research, showed regeneration of native-like tissue between bone and tendon in large animal studies.

Therapeutic areas: Other
Modalities: Tissue-engineered graft (regenerative medicine)
Industry: Biotech

Partnerships

Advanced Regenerative Manufacturing Institute (ARMI)

Beyond the preview

Go deeper on Protherapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Protherapeutics.

Explore the full profile